Comparison of the second-line treatment efficacy in advanced gastric cancer patients previously treated with taxane-based triplet chemotherapy: a Turkish Oncology Group Study

References

• Ajani JA, D’Amico TA, Bentrem DJ, et al. Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20(2):167–192. doi: 10.6004/jnccn.2022.0008.
   PubMed Web of Science ®Google Scholar
• Lordick F, Carneiro F, Cascinu S, et al. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(10):1005–1020. doi: 10.1016/j.annonc.2022.07.004.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24(31):4991–4997. doi: 10.1200/JCO.2006.06.8429.
   PubMed Web of Science ®Google Scholar
• Al-Batran SE, Hartmann JT, Hofheinz R, et al. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol. 2008;19(11):1882–1887. doi: 10.1093/annonc/mdn403.
   PubMed Web of Science ®Google Scholar
• Anter AH, Abdel-Latif RM. The safety and efficacy of fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) combination in the front-line treatment for patients with advanced gastric or gastroesophageal adenocarcinoma: phase II trial. Med Oncol. 2013;30(1):451. doi: 10.1007/s12032-012-0451-1.
   PubMed Web of Science ®Google Scholar
• Gürler F, İlhan A, Güven DC, et al. Does docetaxel matter in metastatic gastric cancer? FOLFOX versus FLOT regimens as first-line treatment. Anticancer Drugs. 2022;33(1):e477–e485. doi: 10.1097/CAD.0000000000001143.
   PubMed Web of Science ®Google Scholar
• Gürler F, Güven DC, Aydemir E, et al. Retrospective comparison of flot and modified dcf as first-line chemotherapy in metastatic gastric adenocarcinoma. Turk J Med Sci. 2022;52(5):1559–1568. doi: 10.55730/1300-0144.5496.
   PubMed Web of Science ®Google Scholar
• Zaanan A, Bouche O, de la Fouchardiere C, et al. LBA77 5-fluorouracil and oxaliplatin with or without docetaxel in the first-line treatment of HER2 negative locally advanced (LA) unresectable or metastatic gastric or gastro-esophageal junction (GEJ) adenocarcinoma (GASTFOX-PRODIGE 51): a randomized phase III trial sponsored by the FFCD. Ann Oncol. 2023;34(suppl_2):S1318. doi: 10.1016/j.annonc.2023.10.078.
   Google Scholar
• Cotes Sanchís A, Gallego J, Hernandez R, et al. Second-line treatment in advanced gastric cancer: data from the Spanish AGAMENON registry. PLoS One. 2020;15(7):e0235848. doi: 10.1371/journal.pone.0235848.
   PubMed Web of Science ®Google Scholar
• Kim HS, Kim HJ, Kim SY, et al. Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis. Ann Oncol. 2013;24(11):2850–2854. doi: 10.1093/annonc/mdt351.
   PubMed Web of Science ®Google Scholar
• Maugeri-Saccà M, Pizzuti L, Sergi D, et al. FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort. J Exp Clin Cancer Res. 2013;32(1):67. doi: 10.1186/1756-9966-32-67.
   PubMedGoogle Scholar
• Catalano V, Graziano F, Santini D, et al. Second-line chemotherapy for patients with advanced gastric cancer: who may benefit? Br J Cancer. 2008;99(9):1402–1407. doi: 10.1038/sj.bjc.6604732.
   PubMed Web of Science ®Google Scholar
• Lorenzen S, Thuss-Patience P, Pauligk C, et al. FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel – results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO. Eur J Cancer. 2022;165:48–57. doi: 10.1016/j.ejca.2022.01.015.
   PubMed Web of Science ®Google Scholar
• Ando T, Hosokawa A, Kajiura S, et al. Efficacy of weekly paclitaxel in patients with advanced gastric cancer refractory to docetaxel-based chemotherapy. Gastric Cancer. 2012;15(4):427–432. doi: 10.1007/s10120-011-0135-0.
   PubMed Web of Science ®Google Scholar
• Iizumi S, Takashima A, Narita Y, et al. Efficacy and safety of taxane monotherapy in advanced gastric cancer refractory to triplet chemotherapy with docetaxel, cisplatin, and S-1: a multicenter retrospective study. Cancer Chemother Pharmacol. 2017;80(3):575–582. doi: 10.1007/s00280-017-3397-3.
   PubMed Web of Science ®Google Scholar
• Ford HE, Marshall A, Bridgewater JA, et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol. 2014;15(1):78–86. doi: 10.1016/S1470-2045(13)70549-7.
   PubMed Web of Science ®Google Scholar
• Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15(11):1224–1235. doi: 10.1016/S1470-2045(14)70420-6.
   PubMed Web of Science ®Google Scholar
• Murray S, Briasoulis E, Linardou H, et al. Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies. Cancer Treat Rev. 2012;38(7):890–903. doi: 10.1016/j.ctrv.2012.02.011.
   PubMed Web of Science ®Google Scholar
• Lombard AP, Liu C, Armstrong CM, et al. ABCB1 mediates cabazitaxel-docetaxel cross-resistance in advanced prostate cancer. Mol Cancer Ther. 2017;16(10):2257–2266. doi: 10.1158/1535-7163.MCT-17-0179.
   PubMed Web of Science ®Google Scholar
• Maloney SM, Hoover CA, Morejon-Lasso LV, et al. Mechanisms of taxane resistance. Cancers (Basel). 2020;12(11):3323. doi: 10.3390/cancers12113323.
   PubMed Web of Science ®Google Scholar
• Mosca L, Ilari A, Fazi F, et al. Taxanes in cancer treatment: activity, chemoresistance and its overcoming. Drug Resist Updat. 2021;54:100742. doi: 10.1016/j.drup.2020.100742.
   PubMed Web of Science ®Google Scholar
• Petrioli R, Pascucci A, Francini E, et al. Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin. Cancer Chemother Pharmacol. 2008;61(1):105–111. doi: 10.1007/s00280-007-0454-3.
   PubMed Web of Science ®Google Scholar
• Lordick F, Lorenzen S, Stollfuss J, et al. Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer. Br J Cancer. 2005;93(2):190–194. doi: 10.1038/sj.bjc.6602697.
   PubMed Web of Science ®Google Scholar